Search hospitals > North Carolina > Pinehurst
FirstHealth of the Carolinas-Moore Regional Hospital
Claim this profilePinehurst, North Carolina 28374
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
154 reported clinical trials
3 medical researchers
Summary
FirstHealth of the Carolinas-Moore Regional Hospital is a medical facility located in Pinehurst, North Carolina. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. FirstHealth of the Carolinas-Moore Regional Hospital is involved with conducting 154 clinical trials across 250 conditions. There are 3 research doctors associated with this hospital, such as Charles S. Kuzma, John W. Byron, and Stephen C. King.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Charles S. KuzmaFirstHealth of the Carolinas-Moore Regional Hospital5 years of reported clinical research
Expert in Lung Cancer
Expert in Cancer
47 reported clinical trials
106 drugs studied
John W. ByronFirstHealth of the Carolinas-Moore Regional Hospital12 years of reported clinical research
Studies Ovarian Cancer
Studies Peritoneal Serous Adenocarcinoma
2 reported clinical trials
7 drugs studied
Stephen C. KingFirstHealth of the Carolinas-Moore Regional Hospital4 years of reported clinical research
Studies Adenocarcinoma
Studies Prostate Adenocarcinoma
1 reported clinical trial
1 drug studied
Clinical Trials running at FirstHealth of the Carolinas-Moore Regional Hospital
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Squamous Cell Carcinoma
Rectal Cancer
Anal Squamous Cell Carcinoma
Colorectal Cancer
Colon Cancer
Anal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at FirstHealth of the Carolinas-Moore Regional Hospital?
FirstHealth of the Carolinas-Moore Regional Hospital is a medical facility located in Pinehurst, North Carolina. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. FirstHealth of the Carolinas-Moore Regional Hospital is involved with conducting 154 clinical trials across 250 conditions. There are 3 research doctors associated with this hospital, such as Charles S. Kuzma, John W. Byron, and Stephen C. King.